129Xe

N/A

Report date: 2026/02/06 20:01:23
NME

Base Information

Drug Name129Xe
Drug Alias NameN/A
ClassificationSmall molecules > Inorganic and minerals salt
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Radiation Injuries +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeuroprotexeon Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of IowaDuke UniversityNational Heart, Lung, And Blood Institute (Nhlbi) +[5] 
Inactive CompaniesThe Brigham and Women's HospitalUniversity Of Wisconsin-MadisonUniversity Of North Carolina At Chapel Hill +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Radiation InjuriesIdiopathic Pulmonary Fibrosis +[5] 
Inactive IndicationsRejection of lung transplantationBronchopulmonary DysplasiaPulmonary Disease, Chronic Obstructive +[6] 

Other Information

ATC CodeN/A
Related LinksN/A